Results 241 to 250 of about 604,769 (337)
This research conducts an in‐depth investigation of cell‐type‐specific regulatory mechanisms underlying molecular and complex phenotypes through integrative analysis of multitissue single‐nucleus RNA sequencing, bulk RNA‐seq, and genome‐wide association study (GWAS) data in pigs.
Lijuan Chen +31 more
wiley +1 more source
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies. [PDF]
Vadalà G +8 more
europepmc +1 more source
ABSTRACT Multiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long‐term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse.
Huiyao Gu +15 more
wiley +1 more source
An Interventional Study on the Late Treatment of Severe Bronchopulmonary Dysplasia in Preterm Infants Using Mesenchymal Stromal Cells. [PDF]
Yildirim S.
europepmc +1 more source
METTL1 and its mediated m7G tRNA modification are significantly up‐regulated after partial hepatectomy (PHx). Overexpression of METTL1 improves the efficiency of liver regeneration after PHx, increases the proliferation of hepatocytes, and accelerates the recovery of liver function.
Manling Huang +18 more
wiley +1 more source
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li +17 more
wiley +1 more source
Harnessing the mechanical microenvironment to optimize mesenchymal stem/stromal cells (MSCs) extracellular vesicle therapeutics. [PDF]
Ragni E, de Girolamo L, Kouroupis D.
europepmc +1 more source
PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao +16 more
wiley +1 more source

